Table 2 |
||||
|
Pharmacokinetics of clindamycin analysed by model-independent and model-dependent approach in patients with sensitive responses in Group-I and II. |
||||
| Pharmacokinetic Parameters |
Model-independent |
Model-dependent |
||
| Group-I (n = 23) |
Group-II (n = 45) |
Group-I (n = 23) |
Group-II (n = 45) |
|
|
|
||||
| tmax (hr) |
2.0 (1.0–4.0) |
3.0 (1.0–4.0) |
2.0 (0.7–3.0) |
2.4 (0.6–4.4) |
| tlag (hr) |
NA |
NA |
0.44 (0.00–0.90) |
0.67 (0.001–1.45) |
| K01 (/hr) |
NA |
NA |
0.62 (0.40–4.00) |
1.48 (0.11–4.00) |
| t1/2a (hr) |
NA |
NA |
1.1 (0.1–1.7) |
0.4 (0.1–6.0) |
| Cmax (μg/ml) |
4.34 (0.89–8.23)a |
6.23 (3.23–25.11) |
3.70 (1.15–5.61)b |
5.79 (3.38–18.11) |
| AUC (μg.hr/ml) |
16.82 (4.07–31.46)c |
39.77 (3.41–136.16) |
21.13 (8.91–37.40)d |
52.91 (28.81–126.73) |
| K10 (/hr) |
NA |
NA |
0.40 (0.15–0.78) |
0.18 (0.09–0.68) |
| t1/2z (hr) |
2.7 (0.7–7.7)e |
4.4 (1.8–11.5) |
NA |
NA |
| t1/2e (hr) |
NA |
NA |
1.0 (0.8–4.7)f |
3.9 (1.0–7.7) |
| CL/F (l/hr) |
11.81 (4.70–68.56) |
11.00 (2.11–332.66) |
14.19 (8.02–33.68) |
11.85 (4.73–42.31) |
| Vz/F (l) |
51.99 (11.45–207.07)g |
72.82 (24.94–896.94) |
NA |
NA |
| V/F (l) |
NA |
NA |
38.12 (26.37–229.06)h |
78.85 (17.85–178.04) |
| Cmin-ss (μg/ml) |
1.99 (0.87–4.56) |
1.54 (0.23–6.98) |
2.24 (0.97–24.00) |
1.66 (0.19–4.93) |
| Cmax-ss (μg/ml) |
4.34 (2.10–14.00)i |
7.23 (3.45–16.54) |
4.80 (1.00–8.47)j |
6.80 (4.10–17.77) |
| Cave-ss (μg/ml) |
2.80 (0.68–5.24) |
3.31 (0.28–11.35) |
1.88 (0.74–5.09)k |
4.41 (2.40–10.56) |
| Cmax-min-ss (μg/ml) |
2.39 (0.22–9.88)l |
5.78 (1.89–13.33) |
2.70 (0.86–4.13)m |
4.96 (2.46–14.80) |
| Fluctuation (%) |
104.4 (5.3–188.4)n |
126.2 (29.2–145.6) |
98.7 (12.9–201.2)° |
158.4 (35.7–159.2) |
|
|
||||
|
Data are presented as median (95% CI). NA = Not applicable a Statistically significant difference from Group-II with p < 0.0001, 95%CI = 1.56(0.80–3.70); b p < 0.0001, 95%CI = 2.01(0.88–4.10); c p = 0.0001, 95%CI = 15.46(8.11–19.23); d p < 0.0001, 95%CI = 15.45(9.11–20.23); e p = 0.0001, 95%CI = 1.5(0.4–1.3);f p = 0.003, 95%CI = 0.8(0.4–4.3); g p = 0.001, 95%CI = 12.65(8.77–20.23); h p = 0.001, 95%CI = 20.14(15.22–50.47); i p < 0.0001, 95%CI = 2.23(0.89–4.55); j p < 0.0001, 95%CI = 1.56(0.89–4.55); k p < 0.0001, 95%CI = 1.12(0.44–2.36); l p = 0.007, 95%CI = 0.78(0.55–1.43); m p < 0.0001, 95%CI = 2.02(1.55–4.23); n p = 0.039, 95%CI = 10.7(2.0–25.1); ° p < 0.0001, 95%CI= 32.2(14.1–50.8) (Mann-Whitney U-test) |
||||
|
Ruangweerayut et al. Malaria Journal 2008 7:225 doi:10.1186/1475-2875-7-225 |
||||
